In an interview with CNBC-TV18, JR Vyas, MD of Dishman Pharma said the the contract research income is going to boost the company's performance through FY13.
first published: Aug 2, 2012 10:40 am
A collection of the most-viewed Moneycontrol videos.
Live: Will Nifty bulls aim to break 25,250 after strong TCS Q2? | Opening Bell
TCS Q2 Earnings Live: Margin, Revenue Beat Street Estimates
Live: Nifty reclaims 25,100 ahead of TCS Q2 results; pharma, metals shine | Closing Bell
Canara Robeco AMC's Rs 1326 Cr IPO Kicks Off | Management Shares Growth Plans| IPO Watch Live
You are already a Moneycontrol Pro user.